

Two Promising agents in ASCO 2009

- PLX4032 (Plexxikon/Roche) :

B-RAF point targeting inhibitors

specific for V600E, oral 960mg bid

9/16 PR, 5/16 SD, 2/16 PD

Progression Free survival: 6-7 months


-ESMO in Sep 2009: 1/27 +18/27+6/27

- Gleevec (Imatinib) in mucosal melanoma

-3/7 PR in exon 11,13 mut

MAP K pathway

receptor



Cell proliferation, growth, survival,
tumor promoting molecules

BRAF V600E mutation

Down regulate tumor suppressor genes

Up regulate tumor promoting molecules

- VEGF, NFkB (nuclear transcription factor kB), c-Met


BRAF V600E mutation

Thyroid cancer – 40-50 %

Melanoma – 60-70 %

Lung adenocarcinoma – 5%

PLX 4032: Phase III



Cross Over not allowed

A SMALL STEP CAN MAKE A BIG DIFFERENCE.

Everyone can help change the world, one step at a time. Whether it's one volunteer hour, one mouse click, or one dollar, you can make a difference with Members Project. Take Charge.SM

GET INVOLVED

MEMBERS PROJECT FROM AMERICAN EXPRESS AND TAKEPART



Search Health 3,000+ Topics

Search input field with Go button

TARGET CANCER

A Roller Coaster Chase for a Cure

By AMY HARMON

Published: February 21, 2010

PHILADELPHIA — His patient, a spunky Italian-American woman in her 60s, was waiting in an exam room down the hall for the answer: Was the experimental drug stopping her deadly skin cancer?

Enlarge This Image



But as Dr. Keith Flaherty read out the measurements of her tumors from the latest CT scan, he could not keep the distress from his voice.

"She's worse," he said to the clinical trial nurse at the University of Pennsylvania's melanoma clinic.

Like the 17 other patients on the drug trial — the corporate lawyer, the receptionist with young children, the Philadelphia philanthropist — the

FACEBOOK

TWITTER

RECOMMEND

COMMENTS (73)

SIGN IN TO E-MAIL

PRINT

SINGLE PAGE

REPRINTS

SHARE



Well

Tara Parker-Pope on Health



Exploring the Links Between Depression and Weight Gain

June 16, 2010

Phys Ed: A Workout for Your Bloodstream

June 16, 2010

Seeking Hope From a Support Group

June 15, 2010

Eating Brown Rice to Cut Diabetes Risk

June 15, 2010

Stupid Teenage Tricks, for a Virtual Audience

June 14, 2010

Get the Opinion Today E-Mail



Sign up for the highlights of the day in Opinion, sent weekday afternoons.

Sign up input field

Sign Up

See Sample | Privacy Policy



Available clinical trials at Hollings

Compassionate Use Trial for Unresectable
Melanoma With Ipilimumab

Available clinical trials at Hollings

A Randomized Phase 3 Study
Tasisulam v.s Paclitaxel
as Second-Line
in Patients with Metastatic Melanoma

Tasisulam ?

- Induces apoptosis via a mitochondrial-dependent mechanism
- Suppresses VEGF-driven cell proliferation
- Given IV for 2 hours every 28 days

- Primary Objective: OS
- Secondary : PFS, RR
- Translational: B-RAF, C-Kit mutation

Available clinical trials at Hollings

A Randomized Phase 3 Study
OncoVex v.s GM-CSF
as Second-Line
in Patients with Metastatic Melanoma

OncoVex ?

- rHSV-1^{hGM-CSF} Oncolytic vaccine
- Genetically engineered HSV based drug.
- GM-CSF is encoded.
- Preferentially proliferate in melanoma cells
- Injected to tumor every 2 weeks for at least 24 weeks (6 months)

Available clinical trials at Hollings

Adjuvant

MAGE A3 vaccination

2:1 randomization

3 weeks x 5 then 3 months x 8

Other options at Hollings

Gamma Knife: Jan 2010

Phase I: MEK inhibitor

Cell therapy: utilize level 4 cell therapy facility